BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
A new crop of AI browsers, notably OpenAI’s ChatGPT Atlas and Perplexity’s Comet, is available to users. But privacy concerns ...
"I join with my brother bishops in acknowledging that we are disturbed seeing a climate of fear and anxiety among our people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback